These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 18507029)

  • 1. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G; Medici MC; Russo GL
    Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
    Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
    Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Wahl H; Tan L; Griffith K; Choi M; Liu JR
    Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria.
    Gao X; Deeb D; Jiang H; Liu YB; Dulchavsky SA; Gautam SC
    J Exp Ther Oncol; 2005; 5(1):39-48. PubMed ID: 16416600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
    Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S; Pirnia F; Miescher D; Krajewski S; Borner MM; Reed JC; Schmid RA
    Oncogene; 2003 Aug; 22(35):5427-35. PubMed ID: 12934102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
    Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
    Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
    Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.